Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects

Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and safety in healthy Chinese subjects. Methods This p...

Full description

Bibliographic Details
Main Authors: Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-11-01
Series:Dermatology and Therapy
Subjects:
Chinese subjects
Deucravacitinib
Pharmacokinetics
Psoriasis
Safety
Tyrosine kinase 2 inhibitor
Online Access:https://doi.org/10.1007/s13555-023-01050-7

Internet

https://doi.org/10.1007/s13555-023-01050-7

Similar Items